

Anjan Debnath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2057114/publications.pdf>

Version: 2024-02-01

59
papers

1,776
citations

346980

22
h-index

325983

40
g-index

62
all docs

62
docs citations

62
times ranked

2384
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Machine Learning-Based Cysticidal Assay and Identification of an Amebicidal and Cysticidal Marine Microbial Metabolite against <i>Acanthamoeba</i> . <i>Microbiology Spectrum</i> , 2022, 10, e0007722.	1.2	4
2	Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008425.	1.3	10
3	Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1099-1106.	2.0	15
4	<i>Acanthamoeba</i> Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1427-1441.	2.0	14
5	Evaluation of Amebicidal and Cysticidal Activities of Antifungal Drug Isavuconazonium Sulfate against <i>Acanthamoeba</i> T4 Strains. <i>Pharmaceuticals</i> , 2021, 14, 1294.	1.7	7
6	Domain-Swap Dimerization of <i>Acanthamoeba castellanii</i> CYP51 and a Unique Mechanism of Inactivation by Isavuconazole. <i>Molecular Pharmacology</i> , 2020, 98, 770-780.	1.0	2
7	In Vitro Evaluation of Farnesyltransferase Inhibitor and its Effect in Combination with 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor against <i>Naegleria fowleri</i> . <i>Pathogens</i> , 2020, 9, 689.	1.2	4
8	HMG-CoA Reductase Inhibitors as Drug Leads against <i>Naegleria fowleri</i> . <i>ACS Chemical Neuroscience</i> , 2020, 11, 3089-3096.	1.7	13
9	In Vitro Effect of Pitavastatin and Its Synergistic Activity with Isavuconazole against <i>Acanthamoeba castellanii</i> . <i>Pathogens</i> , 2020, 9, 681.	1.2	4
10	Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15726-15751.	2.9	17
11	The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against <i>Acanthamoeba castellanii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	23
12	Activity of Auranofin against Multiple Genotypes of <i>Naegleria fowleri</i> and Its Synergistic Effect with Amphotericin B <i>In Vitro</i> . <i>ACS Chemical Neuroscience</i> , 2020, 11, 2464-2471.	1.7	22
13	Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008150.	1.3	20
14	Mechanistic Insights into Cytochrome P450 Inactivation by Azole Drugs in <i>Acanthamoeba castellanii</i> . <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
15	Title is missing!. , 2020, 14, e0008150.		0
16	Title is missing!. , 2020, 14, e0008150.		0
17	Title is missing!. , 2020, 14, e0008150.		0
18	Title is missing!. , 2020, 14, e0008150.		0

#	ARTICLE	IF	CITATIONS
19	Editorial: Recent Progresses in Amebiasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 247.	1.8	8
20	Predictors of Failure from Primary Therapy for Giardiasis in San Diego: A Single Institution Retrospective Review. <i>Pathogens</i> , 2019, 8, 165.	1.2	4
21	Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amoebae <i>Naegleria</i> , <i>Acanthamoeba</i> and <i>Balamuthia</i> . <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 80-94.	1.4	18
22	Identification of Four Amoebicidal Nontoxic Compounds by a Molecular Docking Screen of <i>Naegleria fowleri</i> Sterol 7-Isomerase and Phenotypic Assays. <i>ACS Infectious Diseases</i> , 2019, 5, 2029-2038.	1.8	6
23	Bioactivity of Farnesyltransferase Inhibitors Against <i>Entamoeba histolytica</i> and <i>Schistosoma mansoni</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 180.	1.8	12
24	Identification of cysteine protease inhibitors as new drug leads against <i>Naegleria fowleri</i> . <i>Experimental Parasitology</i> , 2018, 188, 36-41.	0.5	18
25	Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 11349-11371.	2.9	22
26	Highly Potent 1H-1,2,3-Triazole-Tethered Isatin-Metronidazole Conjugates Against Anaerobic Foodborne, Waterborne, and Sexually-Transmitted Protozoal Parasites. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 380.	1.8	18
27	Enzymatic chokepoints and synergistic drug targets in the sterol biosynthesis pathway of <i>Naegleria fowleri</i> . <i>PLoS Pathogens</i> , 2018, 14, e1007245.	2.1	33
28	In Vitro Efficacy of Ebselen and BAY 11-7082 Against <i>Naegleria fowleri</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 414.	1.5	34
29	Cysteine proteases in protozoan parasites. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006512.	1.3	104
30	<i>Entamoeba histolytica</i> : from high-throughput technology to new drugs. , 2018, , .		0
31	Susceptibility Testing of Medically Important Parasites. <i>Clinical Microbiology Reviews</i> , 2017, 30, 647-669.	5.7	9
32	Nf-GH, a glycosidase secreted by <i>Naegleria fowleri</i> , causes mucin degradation: an <i>in vitro</i> and <i>in vivo</i> study. <i>Future Microbiology</i> , 2017, 12, 781-799.	1.0	15
33	Design, synthesis and preliminary antimicrobial evaluation of N-alkyl chain-tethered C-5 functionalized bis-isatins. <i>MedChemComm</i> , 2017, 8, 1982-1992.	3.5	16
34	Editorial: Drug Development for Parasite-Induced Diarrheal Diseases. <i>Frontiers in Microbiology</i> , 2017, 8, 577.	1.5	2
35	<i>Larrea tridentata</i> : A novel source for anti-parasitic agents active against <i>Entamoeba histolytica</i> , <i>Giardia lamblia</i> and <i>Naegleria fowleri</i> . <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005832.	1.3	30
36	CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006104.	1.3	45

#	ARTICLE	IF	CITATIONS
37	Nitroimidazole carboxamides as antiparasitic agents targeting <i>Giardia lamblia</i> , <i>Entamoeba histolytica</i> and <i>Trichomonas vaginalis</i> . <i>European Journal of Medicinal Chemistry</i> , 2016, 120, 353-362.	2.6	47
38	Auranofin inactivates <i>Trichomonas vaginalis</i> thioredoxin reductase and is effective against trichomonads in vitro and in vivo. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 690-694.	1.1	32
39	X-ray structures of thioredoxin and thioredoxin reductase from <i>Entamoeba histolytica</i> and prevailing hypothesis of the mechanism of Auranofin action. <i>Journal of Structural Biology</i> , 2016, 194, 180-190.	1.3	60
40	<i>Naegleria fowleri</i> after 50 years: is it a neglected pathogen?. <i>Journal of Medical Microbiology</i> , 2016, 65, 885-896.	0.7	47
41	Heat shock protein 90 inhibitors repurposed against <i>Entamoeba histolytica</i> . <i>Frontiers in Microbiology</i> , 2015, 6, 368.	1.5	13
42	Metronidazole-triazole conjugates: Activity against <i>Clostridium difficile</i> and parasites. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 96-102.	2.6	48
43	Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003534.	1.3	88
44	Drug Development: Old Drugs and New Lead. , 2015, , 553-564.		2
45	<i>In Vitro</i> Efficacy of Corifungin against <i>Acanthamoeba castellanii</i> Trophozoites and Cysts. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1523-1528.	1.4	20
46	Hsp90 Inhibitors as New Leads To Target Parasitic Diarrheal Diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4138-4144.	1.4	39
47	A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant <i>Giardia lamblia</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2029-2035.	1.4	136
48	Reprofiled drug targets ancient protozoans. <i>Gut Microbes</i> , 2013, 4, 66-71.	4.3	61
49	Corifungin, a New Drug Lead against <i>Naegleria</i> , Identified from a High-Throughput Screen. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5450-5457.	1.4	65
50	A high-throughput drug screen for <i>Entamoeba histolytica</i> identifies a new lead and target. <i>Nature Medicine</i> , 2012, 18, 956-960.	15.2	290
51	Mining a Cathepsin Inhibitor Library for New Antiparasitic Drug Leads. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1023.	1.3	44
52	Antiparasitic activities of novel, orally available fumagillin analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5128-5131.	1.0	23
53	Bis-Acridines as Lead Antiparasitic Agents: Structure-Activity Analysis of a Discrete Compound Library In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2164-2172.	1.4	26
54	A phagocytosis mutant of <i>Entamoeba histolytica</i> is less virulent due to deficient proteinase expression and release. <i>Experimental Parasitology</i> , 2007, 115, 192-199.	0.5	47

#	ARTICLE	IF	CITATIONS
55	Transcriptional and secretory responses of <i>Entamoeba histolytica</i> to mucins, epithelial cells and bacteria. <i>International Journal for Parasitology</i> , 2007, 37, 897-906.	1.3	24
56	<i>Entamoeba histolytica</i> : Characterization of human collagen type I and Ca ²⁺ activated differentially expressed genes. <i>Experimental Parasitology</i> , 2005, 110, 214-219.	0.5	17
57	Identification of Genomic Responses to Collagen Binding by Trophozoites of <i>Entamoeba histolytica</i> . <i>Journal of Infectious Diseases</i> , 2004, 190, 448-457.	1.9	24
58	Genes induced by a high-oxygen environment in <i>Entamoeba histolytica</i> . <i>Molecular and Biochemical Parasitology</i> , 2004, 133, 187-196.	0.5	72
59	Characterization of Plasma Membrane-Associated Antigens of Diagnostic and Prophylactic Importance in <i>Entamoeba histolytica</i> . <i>Archives of Medical Research</i> , 2000, 31, S21-S22.	1.5	0